|
CDX, PDX | Oncology | Lung Cancer | NSCLC- Lung Cancer | HCC827, LU1235, LU1868 | A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors | NA | 2016 |
|
PDX | Oncology | Esophageal Cancer | ESCC - Esophageal Cancer | ES0026, ES0042, ES0110, ES0136, ES0141, ES0172, ES0176, ES0178, ES0191, ES0195, ES0199, ES0201, ES0204, ES0215, ES0219, ES2116 | A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification | H Hanting Zhu, C Chunyu Wang, J Jingjing Wang, D Dawei Chen, J Jiaying Deng, J Jianyun Deng, J Jianhong Fan, H Harun Badakhshi, X Xuesong Huang, L Likun Zhang, J Jie Cai, S Sheng Guo, W Wubin Qian, Y Yongzhan Nie, Q Qixiang Li, K Kuaile ZhaoH Hanting Zhu , et al. | 2018 |
|
PDX | Oncology | Acute Myeloid Leukemia | M5 - Acute Myeloid Leukemia | AM7577 | AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes | NA | 2017 |
|
NA | Immuno-Oncology, Inflammation | NA | NA | NA | Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells | NA | 2021 |
|
PDX | Oncology | Acute Myeloid Leukemia | NA | AM7577 | AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations | NA | 2021 |
|
CDX | Oncology | Lung Cancer | NSCLC (EGFR hi) - Lung Cancer | HCC827 | Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib | NA | 2020 |
|
PDX | Oncology | Lung Cancer | NSCLC- Lung Cancer | LU0387 | Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions | NA | 2018 |
|
PDX, Sygeneic | Oncology | Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Ovarian Cancer | NA | NA | Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice | NA | 2020 |
|
NA | NA | NA | NA | NA | Assessing therapy response in patient-derived xenografts. | J Janosch Ortmann, L Ladislav Rampášek, E Elijah Tai, AS Arvind Singh Mer, R Ruoshi Shi, EL Erin L Stewart, C Celine Mascaux, A Aline Fares, NA Nhu-An Pham, G Gangesh Beri, C Christopher Eeles, D Denis Tkachuk, C Chantal Ho, S Shingo Sakashita, J Jessica Weiss, X Xiaoqian Jiang, G Geoffrey Liu, DW David W Cescon, CA Catherine A O'Brien, S Sheng Guo, MS Ming-Sound Tsao, B Benjamin Haibe-Kains, A Anna GoldenbergJ Janosch Ortmann , et al. | 2021 |
|
CDX, Cell lines, Organoids, PDX | NA | NA | NA | NA | Authentication, characterization and contamination detection of cell lines, xenografts and organoids by barcode deep NGS sequencing | NA | 2020 |
|
NA | Immuno-Oncology, Inflammation | NA | NA | NA | Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases | NA | 2021 |
|
PDX | Immuno-Oncology, Oncology | Bladder Cancer, Gastric Cancer, Lung Cancer | NA | NA | c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors | NA | 2017 |
|
PDX | Oncology | Colorectal Cancer | NA | CR0170, CR0193, CR0196, CR0231, CR0588, CR2110, CR2502, CR2520 | Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature | S Sheng Guo, D Dawei Chen, X Xuesong Huang, J Jie Cai, JP Jean-Pierre Wery, QX Qi-Xiang LiS Sheng Guo , et al. | 2016 |
|
PDX | Immuno-Oncology | Colorectal Cancer | Mucinous adenocarcinoma - Gastric Cancer | CR0004, CR0010, CR0012, CR0024, CR0028, CR0029, CR0047, CR0133, CR11377 | Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature | NA | 2017 |
|
PDX | Oncology | Gastric Cancer | NA | GA0060 | Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer | NA | 2019 |
|
NA | Immuno-Oncology, Inflammation | NA | NA | NA | Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment | NA | 2022 |
|
NA | NA | NA | NA | NA | Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification. | T Ting Liu, J Jianan Rao, W Wenting Hu, B Bowen Cui, J Jiaoyang Cai, Y Yuhan Liu, H Huiying Sun, X Xiaoxiao Chen, Y Yanjing Tang, J Jing Chen, X Xiang Wang, H Han Wang, W Wubin Qian, B Binchen Mao, S Sheng Guo, R Ronghua Wang, Y Yu Liu, S Shuhong ShenT Ting Liu , et al. | 2022 |
|
CDX, GEMM | Immuno-Oncology | Acute Lymphoblastic Leukemia, Adrenal gland Cancer | NA - Adrenal gland Cancer, T - Acute Lymphoblastic Leukemia | AD0484 | DNA-Damage-Induced Alternative Splicing of p53 | J Jing Chen, D Dadong Zhang, X Xiaodi Qin, K Kouros Owzar, JJ Jennifer J McCann, MB Michael B KastanJ Jing Chen , et al. | 2021 |
|
PDX | Oncology | Colorectal Cancer | NA | CR2518, CR2545 | Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors | NA | 2017 |
|
PDX | Oncology | Pancreatic Cancer | NA | NA | Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells | NA | 2017 |
|
CDX, PDX | Oncology | Lung Cancer | NSCLC- Lung Cancer | HCC827, LU0387 | EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor | NA | 2016 |
|
PDX | Oncology | Gastric Cancer | NA | NA | EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab | X Xiaohong Wang, R Runjia Fu, Y Ying Hu, H Hong Du, S Shuangxi Li, Z Ziyu Li, Y Yiqiang Liu, Q Qixiang Li, L Lianhai Zhang, J Jiafu JiX Xiaohong Wang , et al. | 2017 |
|
PDX | Immuno-Oncology | Lung Cancer | NSCLC- Lung Cancer | LU0858, LU1868 | Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer | LA Louise A Koopman, MG Mikkel G Terp, GG Gijs G Zom, ML Maarten L Janmaat, K Kirstine Jacobsen, E Elke Gresnigt-van den Heuvel, M Marcel Brandhorst, U Ulf Forssmann, F Freddy de Bree, N Nora Pencheva, A Andreas Lingnau, MA Maria A Zipeto, PW Paul Whi Parren, EC Esther Cw Breij, HJ Henrik J DitzelLA Louise A Koopman , et al. | 2019 |
|
PDX | Immuno-Oncology, Inflammation | Lung Cancer | NSCLC- Lung Cancer | LU2503, LU5381 | Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models | NA | 2017 |
|
HuGEMM, MiXeno | Immuno-Oncology, Oncology | Lung Cancer | NSCLC- Lung Cancer | HCC827 | HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties | NA | 2020 |
|
MuPrime | Oncology | Pancreatic Cancer | Ductal adenocarcinoma - Pancreatic Cancer | NA | Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry | X Xiaoyu An, X Xuesong Ouyang, H Hui Zhang, T Tingting Li, YY Yu-Yang Huang, Z Zhiyuan Li, D Demin Zhou, QX Qi-Xang LiX Xiaoyu An , et al. | 2018 |
|
CDX, GEMM, HuCell | Oncology | Adrenal gland Cancer, Bladder Cancer | ADC - Bladder Cancer, Sarcoma - Bladder Cancer, SCC - Bladder Cancer, TCC - Bladder Cancer | AD0484, AL5514, AL5518, AL5521, AL8223 | In Vivo Pharmacology Models for Cancer Target Research | D Dawei Chen, X Xiaoyu An, X Xuesong Ouyang, J Jie Cai, D Demin Zhou, QX Qi-Xiang LiD Dawei Chen , et al. | 2020 |
|
PDX | Oncology | Kidney Cancer | RCC - Kidney Cancer | KI2367, KI2368 | Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models | B Baoan Hong, Y Yong Yang, S Sheng Guo, S Shayiremu Duoerkun, X Xiaohu Deng, D Dawei Chen, S Shijun Yu, W Wubin Qian, Q Qixiang Li, Q Qing Li, K Kan Gong, N Ning ZhangB Baoan Hong , et al. | 2017 |
|
PDX | Oncology | NA | NA | NA | MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage | NA | 2021 |
|
PDX | Oncology | Lung Cancer | NA | LU0387 | Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer | NA | 2018 |
|
PDX | Oncology | Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer | NA | NA | Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor | NA | 2019 |
|
PDX | Immuno-Oncology, Oncology | Gastric Cancer | ADC - Gastric Cancer | GA0055 | MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity | NA | 2018 |
|
Organoids | Oncology | NA | NA | NA | New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids | NA | 2021 |
|
MuPrime | Oncology | Bladder Cancer, Sarcoma, Skin Cancer | NA | BL6078, SA9003, SK6005 | Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models | NA | 2019 |
|
PDX | Oncology | Lung Cancer | NSCLC- Lung Cancer | LU0387, LU0858, LU1235, LU1868, LU3075 | NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors | M Mengmeng Yang, X Xiaoxi Xu, J Jie Cai, J Jinying Ning, JP Jean Pierre Wery, QX Qi-Xiang LiM Mengmeng Yang , et al. | 2016 |
|
PDX | Oncology | Colorectal Cancer | NA | CR3496, CR3547, CR3612, CR6227, MC3405 | Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor | NA | 2017 |
|
CDX, GEMM, HuCell, HuGEMM, Humanized models, MiXeno, MuPrime, Organoids, PDX, Sygeneic | Immuno-Oncology | NA | NA | NA | Preclinical pharmacology modeling of chimeric antigen receptor T therapies | NA | 2021 |
|
CDX | NA | Acute Graft versus Host Disease | NA | AD0344 | Resorbable and highly elastic block copolymers from 1,5-dioxepan-2-one and L-lactide with controlled tensile properties and hydrophilicity. | M Maria Ryner, AC Ann-Christine AlbertssonM Maria Ryner , et al. | 2021 |
|
PDX | Oncology | Colorectal Cancer | NA | CR1520, CR2502, CR2518, CR2520 | RET fusions observed in lung and colorectal cancers are sensitive to ponatinib | NA | 2018 |
|
PDX | Oncology | Colorectal Cancer | ADC - Colorectal Cancer | CR2518 | RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies | NA | 2020 |
|
PDX | Oncology | GIST | NA | NA | Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants | NA | 2019 |
|
CDX, HuCell | NA | NA | NA | NA | Robotic Radical Cystectomy Outcomes after Intervention for Prostate Cancer. | NH Neel H Patel, G Gus Miranda, J Jie Cai, MM Mihir M Desai, I Inderbir Gill, M Monish AronNH Neel H Patel , et al. | 2020 |
|
PDX | Oncology | Colorectal Cancer | ADC - Colorectal Cancer, NSCLC- Lung Cancer | CR2518, CR2545 | Selective RET kinase inhibition for patients with RET-altered cancers | NA | 2018 |
|
PDX | Oncology | Lymphoma | B cell lymphoma - Lymphoma, B cell lymphoma (ABC/GCB, MYD88 L265P) - Lymphoma, NHL - Lymphoma, NHL (DLBCL, ABC) - Lymphoma | LY0257, LY2298 | Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT | NA | 2017 |
|
HuCell, HuGEMM | Immuno-Oncology | NA | NA | NA | Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment | NA | 2021 |
|
PDX | Oncology | Colorectal Cancer | ADC, mucinous adenocarcinoma - Colorectal Cancer, Adenocarcinoma - Colorectal Cancer | CR2506, CR3150 | Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function | NA | 2016 |
|
CDX, HuGEMM, MiXeno | Immuno-Oncology, Inflammation | Bladder Cancer, Brain Cancer | ADC - Bladder Cancer, Astrocytoma - Brain Cancer, SCC - Bladder Cancer, TCC - Bladder Cancer, Transition cell carcinoma - Bladder Cancer | AD0484, AD10272, AL5511, BL3249 | The design, analysis and application of mouse clinical trials in oncology drug development | S Sheng Guo, X Xiaoqian Jiang, B Binchen Mao, QX Qi-Xiang LiS Sheng Guo , et al. | 2019 |
|
PDX | Oncology | Sarcoma | Ewing's Sarcoma - Sarcoma | SA10233 | The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity | DAR Daniel A R Heisey, TL Timothy L Lochmann, KV Konstantinos V Floros, CM Colin M Coon, KM Krista M Powell, S Sheeba Jacob, ML Marissa L Calbert, MS Maninderjit S Ghotra, GT Giovanna T Stein, YK Yuki Kato Maves, SC Steven C Smith, CH Cyril H Benes, JD Joel D Leverson, AJ Andrew J Souers, SA Sosipatros A Boikos, AC Anthony C FaberDAR Daniel A R Heisey , et al. | 2018 |
|
CDX, HuCell | Oncology | Bladder Cancer | NA - Bladder Cancer, Sarcoma - Bladder Cancer, SCC - Bladder Cancer | AD0484, AL5511, BL3249 | The Immune Landscape of Cancer | V Vésteinn Thorsson, DL David L Gibbs, SD Scott D Brown, D Denise Wolf, DS Dante S Bortone, TH Tai-Hsien Ou Yang, E Eduard Porta-Pardo, GF Galen F Gao, CL Christopher L Plaisier, JA James A Eddy, E Elad Ziv, AC Aedin C Culhane, EO Evan O Paull, IKA I K Ashok Sivakumar, AJ Andrew J Gentles, R Raunaq Malhotra, F Farshad Farshidfar, A Antonio Colaprico, JS Joel S Parker, LE Lisle E Mose, NS Nam Sy Vo, J Jianfang Liu, Y Yuexin Liu, J Janet Rader, V Varsha Dhankani, SM Sheila M Reynolds, R Reanne Bowlby, A Andrea Califano, AD Andrew D Cherniack, D Dimitris Anastassiou, D Davide Bedognetti, Y Younes Mokrab, AM Aaron M Newman, A Arvind Rao, K Ken Chen, A Alexander Krasnitz, H Hai Hu, TM Tathiane M Malta, H Houtan Noushmehr, CS Chandra Sekhar Pedamallu, S Susan Bullman, AI Akinyemi I Ojesina, A Andrew Lamb, W Wanding Zhou, H Hui Shen, TK Toni K Choueiri, JN John N Weinstein, J Justin Guinney, J Joel Saltz, RA Robert A Holt, CS Charles S Rabkin, , AJ Alexander J Lazar, JS Jonathan S Serody, EG Elizabeth G Demicco, ML Mary L Disis, BG Benjamin G Vincent, I Ilya ShmulevichV Vésteinn Thorsson , et al. | 2019 |
|
PDX | Immuno-Oncology, Oncology | Lung Cancer | NSCLC- Lung Cancer | LU1147, LU11693, LU2512, LU6405 | The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients | NA | 2020 |
|
PDX | Immuno-Oncology, Oncology | Kidney Cancer | CCRCC - Kidney Cancer | NA | Transcriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese population | Q Qiang Zhao, J Jia Xue, B Baoan Hong, W Wubin Qian, T Tiezhu Liu, B Bin Fan, J Jie Cai, Y Yongpeng Ji, J Jia Liu, Y Yong Yang, Q Qixiang Li, S Sheng Guo, N Ning ZhangQ Qiang Zhao , et al. | 2020 |
|
PDX, Sygeneic | Immuno-Oncology, Oncology | NA | NA | NA | Tumor Purity in Preclinical Mouse Tumor Models | NA | 2022 |
|
PDX | Oncology | Lung Cancer | SCLC - Lung Cancer | LU5263 | Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression | TL Timothy L Lochmann, KV Konstantinos V Floros, M Mitra Naseri, KM Krista M Powell, W Wade Cook, RJ Ryan J March, GT Giovanna T Stein, P Patricia Greninger, YK Yuki Kato Maves, LR Laura R Saunders, SJ Scott J Dylla, C Carlotta Costa, SA Sosipatros A Boikos, JD Joel D Leverson, AJ Andrew J Souers, GW Geoffrey W Krystal, H Hisashi Harada, CH Cyril H Benes, AC Anthony C FaberTL Timothy L Lochmann , et al. | 2017 |